Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7240960 | 0.89 | TERT (0.58) | TERTHDAC1HDAC2ALOX15HTT | |
| SCHEMBL29355750 | 0.85 | TERT (1.00) | TERTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL29362821 | 0.85 | TERT (1.00) | TERTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL16964998 | 0.85 | TERT (1.00) | TERTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL30760782 | 0.85 | TERT (1.00) | TERTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL29966843 | 0.85 | TERT (1.00) | TERTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL4022937 | 0.85 | TERT (1.00) | TERTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL6790528 | 0.80 | TERT (0.69) | TERTHTTALDH1A1RAB9AGAA | |
| SCHEMBL6785154 | 0.80 | TERT (0.84) | TERTALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6786614 | 0.79 | TERT (0.59) | TERTHDAC1HDAC2ALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | claimed |
| WO-2009100323-A2 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY (US) | 2009-08-13 | — | — | WO | claimed |
| US-20020123509-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-05 | — | — | US | claimed |
| WO-2002051830-A1 | CARBOXAMIDES FOR USE AS TELOMERASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-04 | — | — | WO | claimed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | disclosed |
| WO-2009100323-A2 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
| US-6660764-B2 | Telomerase inhibitors such as trans-3-(benzothien-6-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide; use as antitumor agent | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20020123509-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002051830-A1 | CARBOXAMIDES FOR USE AS TELOMERASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | NAAA, ELANE, APEH | TERT 1053/4885HDAC1 1270/4885HDAC2 1304/4885 |
| US-20020123509-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | ASS1, ADCY1, ADCY3 | TERT 4749/4885HDAC1 461/4885HDAC2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.